Browse the corpus

Isoproterenol, also known as isoprenaline, is a nonselective beta-1 and beta-2 adrenergic receptor agonist primarily used in the management of bradydysrhythmias and for electrophysiologic evaluation in supervised clinical settings. The administration and postadministration monitoring of this drug are complex and require a coordinated interprofessional approach to ensure safe and effective use. Structurally similar to epinephrine, isoproterenol increases heart rate and myocardial contractility while producing peripheral vasodilation and bronchodilation. Approved by the US Food and Drug Administration (FDA) in 1947, isoproterenol has both FDA-approved and off-label clinical applications. This activity reviews the indications, mechanism of action, pharmacokinetics, dosing considerations, adverse effect profile, contraindications, and clinically significant drug interactions of isoproterenol. Given the drug’s potent cardiovascular effects and narrow therapeutic margin, its administration and monitoring require careful patient selection and close interprofessional collaboration. This activity is grounded in evidence-based medicine and is designed to improve overall patient care and clinical outcomes. In addition, this activity emphasizes the importance of interprofessional collaboration among healthcare providers in managing isoproterenol therapy and provides them with essential knowledge and practical tools for its optimal administration. By understanding the complex pharmacology of isoproterenol, healthcare professionals can optimize therapy by focusing on strategies to minimize adverse reactions while maximizing therapeutic effectiveness, aiming to deliver safe, effective, and individualized patient care, minimize adverse events, and improve patient outcomes. Objectives: Identify FDA-labeled and evidence-supported off-label indications for isoproterenol in acute and perioperative care settings. Apply evidence-based dosing strategies and titration parameters for isoproterenol in adult and pediatric patients. Implement appropriate monitoring strategies, including electrocardiographic and hemodynamic surveillance, during isoproterenol administration. Collaborate with interprofessional healthcare teams to optimize isoproterenol therapy and reduce preventable medication-related complications. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Acute toxicity from isoproterenol can cause a significant decrease in blood pressure. Accidental overdose is most commonly manifested by tachycardia or other arrhythmias, hypotension or hypertension, and angina. In such cases, the rate of isoproterenol administration should be reduced or the drug discontinued until the patient stabilizes. Continuous monitoring of pulse, respiratory rate, electrocardiography, and blood pressure is recommended. Management of Overdose No known antidote exists for isoproterenol toxicity, although investigational therapies are under study.[24] Management is primarily supportive. Recent animal research indicates that, in isoproterenol-induced heart failure, empagliflozin and sacubitril/valsartan might offer cardioprotective effects and could serve as potential treatment options. Nonetheless, definitive conclusions require larger, evidence-based studies in humans.[25]

Isoproterenol is most commonly prescribed by a cardiologist; however, its use requires close coordination among an interprofessional healthcare team. This team typically includes intensivists, cardiologists, cardiac surgeons, critical care specialists, pharmacists, and ICU nursing staff. Isoproterenol is administered exclusively as an intravenous infusion and is generally reserved for severe bradycardia, heart block, or cardiac arrest. In select circumstances, it may also be used to manage hypovolemic shock or bronchospasm. Due to its potent beta-adrenergic effects, isoproterenol can precipitate tachyarrhythmias and hypertension, particularly at higher doses. When administered in the ICU setting, continuous hemodynamic and electrocardiographic monitoring is required for patients. With the widespread availability of pacemakers and alternative chronotropic agents, the clinical use of isoproterenol has declined in the current medical paradigm.[26] Effective and safe use of isoproterenol depends on interprofessional collaboration among healthcare providers. While the ordering clinician determines the indication and initiates therapy, optimal management requires active involvement from the entire care team. Pharmacists play a critical role in verifying dosing, preparing infusions, and conducting thorough medication reconciliation. Consultation with a board-certified cardiology pharmacist is particularly valuable, given their expertise in cardiovascular pharmacotherapy, drug interactions, dose adjustments, and monitoring for adverse effects. Nursing staff are on the front line of obtaining accurate medication histories and performing the ongoing monitoring required during isoproterenol administration. Any abnormal findings or clinical concerns should be promptly communicated to the healthcare team, including prescribing clinicians and pharmacists, to allow timely dose adjustments or therapy modifications. This level of coordination is essential given the severity of the conditions treated with isoproterenol and the potential for significant adverse effects or drug interactions. Nursing staff with specialized training in cardiology or critical care can provide additional clinical insight and enhance patient safety. Effective, collaborative interprofessional communication is essential to optimize isoproterenol therapy, improve clinical outcomes, and minimize adverse events.